Develops treatments for cancer and infectious diseases, focusing on novel small molecule therapies.
Sunshine Biopharma, Inc. is a pharmaceutical and nutritional supplement company based in Pointe-Claire, Canada, specializing in the research and development of anticancer drugs and science-based nutritional supplements. The company's flagship anticancer drug candidate, Adva-27a, is a GEM-difluorinated C-glycoside derivative of podophyllotoxin designed to target a broad spectrum of cancers, including leukemia, lymphoma, lung, brain, prostate, ovarian, and liver cancers. Notably, Adva-27a has demonstrated efficacy in killing multidrug-resistant cancer cells, such as those found in pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells.
In response to emerging health challenges, Sunshine Biopharma is also developing SBFM-PL4, an anti-coronavirus treatment compound aimed at addressing the ongoing global pandemic. This initiative underscores the company's commitment to leveraging its research capabilities to combat infectious diseases and improve public health outcomes.
Additionally, Sunshine Biopharma markets Essential 9, a nutritional supplement tablet, and a Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name. These products complement the company's focus on enhancing overall health and well-being through scientifically formulated nutritional solutions. With a license agreement in place with the University of Georgia, Sunshine Biopharma continues to advance the development of its lead anti-coronavirus compound, SBFM-PL4, underscoring its dedication to innovation in both pharmaceuticals and nutritional supplements.